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Nanocarriers have been explored to improve the delivery of tumor antigens to dendritic cells (DCs). Gold
nanoparticles are attractive nanocarriers because they are inert, non-toxic, and can be readily endocytosed by DCs.
Here, we designed novel gold-based nanovaccines (AuNVs) using a simple self-assembling bottom-up conjugation
method to generate high-peptide density delivery and effective immune responses with limited toxicity. AuNVs
were synthesized using a self-assembling conjugation method and optimized using DC-to-splenocyte interferon-γ
enzyme-linked immunosorbent spot assays. The AuNV design has shown successful peptide conjugation with
approximately 90% yield while remaining smaller than 80 nm in diameter. DCs uptake AuNVs with minimal toxicity
and are able to process the vaccine peptides on the particles to stimulate cytotoxic T lymphocytes (CTLs). These
high-peptide density AuNVs can stimulate CTLs better than free peptides and have great potential as carriers for
various vaccine types.
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Cancer immunotherapy is a promising new strategy that
stimulates the patients' immune systems to target and
kill tumors. Various groups have investigated enhancing
the induction of anti-tumor T cell responses through
vaccines, including immunization with tumor-associated
antigens (TAA) or TAA-derived peptides [1-4]. In phase
I trials, gp100 peptides, a melanocyte lineage-specific
protein expressed in most melanomas, elicited strong
anti-melanoma CD8+ cytotoxic lymphocytes (CTLs) (in
14% of patients) and CD4+ helper T cell effects (in 79%
of patients) [5,6]. In phase III trials, gp100 vaccination
showed favorable progression-free survival for metastatic
melanoma [7]. However, the overall response rate was
only 2.6% with this peptide vaccine method, and the
responses were transient [2]. This low response could be* Correspondence: drezek@rice.edu
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in any medium, provided the original work is pattributed to peptide degradation and diffusion, limiting
the amount of antigen delivered to the peripheral
antigen-presenting cells (APCs), including lymph node-
resident dendritic cells (DC).
To address these issues, several nanocarriers have been
explored to improve the delivery of tumor antigens to
DCs. The four main types of nanoparticles that have
been explored in this capacity are liposomal, viral-based,
polymer-based, and metallic particles [8]. Commonly
used polymeric and liposomal nanoparticles have two
main limiting factors. First, liposomal and polymeric
particles can be toxic under high doses due to mem-
brane fusion and acidic monomers, respectively [8]. Sec-
ond, these particles are greater than 100 nm in diameter
and stay at the injection site, requiring peripheral DCs
to migrate to the lymph nodes for exposure to the vac-
cine antigens [9], whereas smaller nanoparticles (ap-
proximately 45 nm) have been reported to drain into
lymph nodes and are readily taken up by DCs following
subcutaneous (s.c.) injections [9,10]. These studies indi-
cate that sub-100-nm nanocarrier designs can facilitatepen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Gold nanoparticles (AuNPs) are inert, non-toxic, and
can be readily endocytosed by DCs and other phagocytic
mononuclear cells [11-13]. In vitro studies have demon-
strated that even non-phagocytic T cells can load up to
104 particles per cell [14]. The capacity for AuNPs to be
uptaken by cells may allow improved delivery of antigens
and therefore improve the overall vaccine antigen dose
delivered to APCs. Additionally, modifications of AuNPs
are straightforward as molecules with free thiols can
self-assemble into a monolayer on the gold surface by
forming strong gold-sulfide dative bonds. This provides
an efficient and cost-effective platform for antigen deliv-
ery. Although most vaccines use subcutaneous injec-
tions, gold nanoparticles tend to accumulate in the
reticulo-endothelial system when injected intravenously
(i.v.) [15]. For other AuNP-based drug delivery systems,
this phenomenon is commonly viewed as potentially
toxic or can result in adverse side effects. However, for
vaccine delivery, particle accumulation in the spleen can
be very advantageous because it is the largest immune
organ in the body containing significant numbers of
lymphocytes and APCs. Therefore, gold nanovaccines
(AuNVs) can potentially improve the efficacy of both i.v.
and s.c. vaccines.
Most liposomal and polymer formulations use encap-
sulation methods to incorporate vaccine peptides. Mak-
ing smaller particles using this method reduces the
peptide load delivered to innate immune cells. Conven-
tionally, vaccine antigen AuNP complexes are assembled
in two ways: (1) direct conjugation of the peptides onto
the gold surface using the thiols on the cysteine residues
or (2) electrostatic binding of the peptides onto modified
or unmodified gold surfaces [8,16,17]. However, these
methods only allow one layer of peptides or form aggre-
gates electrostatically on the gold surfaces. Thus, we
devised a method to self-assemble large quantities ofAu
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Figure 1 Schematic of gold-based nanovaccine design synthesis. The
SH. The AuNPs were subsequently conjugated with the desired peptides upeptides on AuNPs using a simple 1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide (EDC) and sulfo-N-hydroxysuc-
cinimide (sulfo-NHS) bottom-up conjugation strategy to
layer peptides onto modified AuNPs (Figure 1). The tan-
dem repeats of peptides, incorporated onto this AuNV
design, have shown improved vaccination efficacy in non-
gold particle systems [18,19]. Furthermore, the simple
bottom-up conjugation design can allow effective delivery
of large doses of vaccine peptides and thus improve im-
munogenicity of the vaccine antigen peptides. Here, we
evaluated the high-peptide density AuNVs through three
steps: synthesis and characterization, AuNV uptake by
dendritic cells, and functional in vitro immunologic assays.
Methods
Reagents
All of the polyethylene glycol (PEG) products were pur-
chased from NanoCS (New York, NY, USA). The
citrate-stabilized gold colloids were purchased from Ted
Pella (Redding, CA, USA). All of the buffers and chemi-
cals were purchased from Sigma-Aldrich (St. Louis, MO,
USA), Thermo Scientific (Waltham, MA, USA), and
Invitrogen (Carlsbad, CA, USA). The peptides were pur-
chased from Genemed Synthesis (San Antonio, TX,
USA). The JAWS II cells and media were purchased
from ATCC (Manassas, VA, USA).
Two-step AuNV synthesis
First, carboxyl-PEG-thiols were added to a 30-nm gold
colloid solution (2 × 1011 particles/ml) with an end con-
centration of 5 μM and incubated for 24 h. The solution
was raised to 0.1 M NaCl, 10 mM sodium phosphate,
and 0.1% Tween 20. The excessive PEG molecules were
removed from the AuNP solution by three centrifugation-
washing steps at 7,000×g for 20 min with phosphate-
buffered saline (PBS). The final particle pellet was diluted
with 2-(N-morpholino)ethanesulfonic acid (MES) buffer.
EDC (4.25 mg) and sulfo-NHS linker (6.4 mg) were addedPeptides
EDC/Sulfo-NHS
AuNPs were coated with self-assembled monolayers of 5000-MW PEG-
sing EDC and sulfo-NHS as linkers.
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room temperature. The excessive linkers were removed
from the solution by centrifuging in a 10,000 molecular
weight cutoff filter at 2,000×g for 15 min and diluting the
particles with PBS. The peptides (50 μg) were then added
to the particles per milliliter of solution, and the mixture
was incubated for 30 min, 1 h, 2 h, and 24 h at room
temperature. Varying the incubation time was for
optimization of the conjugation scheme. Hydroxylamine
(10 mM) was added to quench any unbound EDC/NHS
for an additional hour. The peptide-coated particles were
then centrifuged and washed three times with PBS. After
the final PBS wash/centrifuge cycle, the supernatant was
removed, and the particle pellet was re-suspended in 200
μl of PBS. The sample was sonicated and stored at 4C
until used.
One-step AuNV synthesis
After the carboxyl-PEG-AuNPs were suspended in MES
buffer, 5 μl of 44 mM EDC and 5 μl of 59 mM sulfo-
NHS linkers were added per milliliter of particle-MES
solution and incubated for 15 min at room temperature.
The peptides (50 μg) were then added to the particles
per milliliter of solution, and the mixture was incubated
for 1 h. Hydroxylamine (10 mM) was added to quench
any unbound EDC/NHS for an additional hour. The col-
lection process was the same as before. To assess gold
nanoparticle core size on AuNV efficacy, 15-nm and 80-
nm AuNPs were used to synthesize AuNVs. For the 15-
nm and 80-nm AuNVs, the stock particle concentration
started at 1.4 × 1012 and 1.1 × 1010 particles/ml, respect-
ively, as provided by Ted Pella. The conjugation process
was the same.
Splenocyte harvest protocol
C57BL/6J, pmel-1, and OT-I mice (Jackson Laboratories,
Bar Harbor, ME, USA) were maintained in the
pathogen-free mouse facility at Baylor College of Medi-
cine. This study was approved by the Institutional Ani-
mal Care and Use Committees (IACUC) of Baylor
College of Medicine (# A-3823-01). The spleens were
harvested from pmel-1 mice and homogenizing the tis-
sue through a cell strainer formed a single cell suspen-
sion. The cells were collected, and the red blood cells
(RBCs) were lysed to yield a suspension of splenocytes
(2 M/ml) and used within an hour of harvesting. The
OT-I splenocytes were collected through the same
method and were frozen until use in the enzyme-linked
immunosorbent spot (ELISPOT) assays.
Bone marrow-derived dendritic cell harvest and exposure
protocol
The femur and tibia from both sides of a C57BL/6
mouse were harvested and flushed into a petri dish.After lysing the RBCs, the cells were grown on a 10-cm
dish for 48 h at 37C in bone marrow-derived dendritic
cell (BMDC) media supplemented with IL-4 and GM-
CSF. After 2 days, the media was aspirated, and fresh
media was added to the dish for another 2 days. Then,
BMDCs were collected by vigorously rinsing the dish
and plated onto 12-well plates at 2 M cells per well.
After 24 h, the AuNVs and other conditions were added
to each well for another 24 h. The BMDCs were then
washed with PBS to remove any free particles and
diluted to 500,000 cells/ml.
Interferon-γ ELISPOT
Splenocytes (200,000) were added to 96-well plates that
were pre-coated with anti-interferon-γ (IFN-γ) anti-
bodies. Free AuNVs or 50,000 loaded BMDCs were
added to each well and incubated for 24 h at 37C. The
cells were decanted, and then the plate was washed with
PBS/0.05% Tween 20 six times. Biotinylated anti-IFN-γ
antibodies were added to the plate to form sandwich
assays for 2 h at 37C. After washing excess antibodies
off the plate, avidin-peroxidase complexes (Vectastain,
Vector Laboratories, Burlingame, CA, USA) were added
to the plates to bind to the biotin molecules. Spots were
developed by adding 3-amino-9-ethylcarbazole (AEC)
and hydrogen peroxide. The dried membrane was
punched out of the plate, and spots were evaluated by
ZellNet Consulting (Fort Lee, NJ, USA).
Conjugation yield calculation
Trp-2 (1 μg/μl) peptides were diluted into 14 different
concentrations. The 280-nm absorbance values of the
Trp-2 peptides were used to generate a concentration
standard curve. The peak absorbance values in the vis-
ible range (400 to 800 nm) from the dilutions of the 30-
nm gold colloid stock (2 × 1011 particles/ml) were used
to plot against the 280-nm absorbance values. The actual
280-nm absorbance of the Trp-2 peptides was measured
by calculating the difference between the Trp-2 peptide
280-nm absorbance values for the Trp-2 AuNVs and the
standardized 280-nm values from the 30-nm gold col-
loids. The peptide concentration was calculated by cor-
relating the absorbance values to the Trp-2 standard
curve (Additional file 1: Figure S1).
Toxicity test protocol
One-hundred microliters of JAWS II cells, a BMDC cell
line, were added to a 96-well plate (500,000 cells/ml).
Ovalbumin (OVA) or gp100 AuNVs (1 to 10 μl of
1011particles/ml) were added to the cells for 24 h at
37C. Ten microliters of alamarBlue (Life Technologies
Corporation, Carlsbad, CA, USA) was then added to
each well and incubated for 2 h at 37C. The fluorescent
(B) 
(A) 
Figure 2 Characterization of AuNV conjugation process. (A) The
absorbance spectra of the initial peptide AuNP conjugates. The full
view shows the 400- to 800-nm range, and the zoom insert shows
the peaks between 510 and 545 nm. Preconjugate refers to the
carboxyl-PEG-AuNPs. The NH2OH control refers to capping the active
carboxyl groups on the particles with hydroxylamine. The
preconjugates and NH2OH control particles had the same peak,
verifying that the conjugation protocol does not alter the
absorbance peak. The particles conjugated with peptides show a 2-
nm red shift. (B) TEM images of a 30-nm AuNP coated with PEG and
a 30-nm gp100 AuNV. The surface of the peptide-coated AuNV
appears rougher and thicker (red arrow) than the PEG-coated AuNP,
indicating successful conjugation (scale bar = 10 nm).
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with a Fluorolog-3 plate reader.
Lysate degradation study
From the one-step AuNV protocol, 25 μg of fluorescein
isothiocyanate (FITC) fluorescent peptides were added
to the solution prior to hydroxylamine. This step allows
the fluorescent peptides to be on the outside layer of the
AuNVs. JAWS II cells (500,000) were lysed in 1 ml
CHAPS lysis buffer. The particles (1011) were added to
either the CHAPS lysis buffer or to the JAWS II lysate
for 24 h. The particles were removed by centrifuging at
7,000×g for 20 min. The supernatants were transferred
to a 96-well plate, and the FITC fluorescence was mea-
sured at 520 nm (excitation at 485 nm).
Results and discussion
Self-assembled AuNV particle synthesis
First, carboxyl-PEG-thiols were self-assembled onto
citrate-stabilized 30-nm gold colloids to form a mono-
layer. PEG was chosen for its bio-inert and non-toxic
properties and the ability to protect AuNPs during the
conjugation process [20]. Next, EDC and sulfo-NHS lin-
kers in MES buffer were added to the particle solution
for carboxyl activation.
Following the suggested protocol adapted from Grabarek
and Gergely [21], the majority of the excess linkers were
then removed from the solution via a centrifuge filter. The
particles were transferred to PBS buffer, and the vaccine
peptides or hydroxylamine (control) were subsequently
added. This two-step method is best known to allow coup-
ling of the two proteins without strongly affecting the sec-
ond protein's carboxyls. Three MHC class I peptides were
used: one from model antigen OVA (SIINFEKL) and two
from melanoma antigens, gp100 (KVPRNQDWL) and
Trp-2 (SVYDFFVWL) [22,23].
Peptide conjugation was verified by measuring the
optical extinction spectra for preconjugated particles (PEG-
coated 30-nm gold colloids), hydroxylamine (NH2OH) par-
ticles, and gp100 (KVPRNQDWL) AuNVs. The NH2OH
particles (negative controls) underwent the same synthesis
procedures as the gp100 AuNV particles, but NH2OH was
added instead of peptides to quench the EDC reaction. This
control particle accounted for any spectral changes due to
the entire conjugation process. The AuNP peak absorbance
red shifted from 523 to 527 nm when carboxyl-PEG-SH
bound to the particle surface. When the gp100 peptides
were conjugated to the AuNPs, the peak shifted further to
529 nm, indicating successful peptide conjugation onto the
nanoparticle surface. The hydroxylamine control particles'
extinction peak did not red shift, indicating that the red
shift of the AuNV absorbance spectra is not a result of the
conjugation process alone, but is caused by the peptide
linkage (Figure 2A).In Figure 2B, the particles were dried prior to trans-
mission electron microscopy (TEM) imaging, so the
normally hydrated PEG molecules collapsed onto the
AuNP surface, showing a uniform light rim around the
border of the gold particle (Figure 2B). Post-peptide
conjugation, the AuNV TEM images showed thickening
and rough edges on the AuNP surface, which can be
caused by peptide linkage to the PEG molecule and self-
polymerization.
AuNV characterization
Particle size is important for lymphatic drainage from
the injection site, biodistribution, and cellular endocyto-
sis. Dynamic light scattering measurements (DLS) showed
that the OVA AuNVs were less than 80 nm in diameter,
which is much smaller than other liposomal or polymeric
formulations and, therefore, can potentially improve
lymphatic drainage when injected subcutaneously. The
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ties because the gold colloids and COOH-PEG-AuNPs
were capped with either citrate or carboxyls; however, the
OVA AuNVs show near-neutral potentials because the
OVA peptides have no charge at physiologic pH (Table 1).
For conjugation yield approximation, Trp-2 peptides
were used due to the high absorbance of the Y amino
acid at 280 nm. The Trp-2 AuNVs were calculated to
have 24.6 μg of peptide per 1011 particles based on UV–
vis absorbance measurements. After subtraction of the
standard curves, the conjugation yield was calculated to
be approximately 90% (Additional file 1: Figure S1).
Dendritic cell uptake of AuNVs
After characterization of the AuNVs, the next step was
to evaluate their interaction with dendritic cells. Using
dark-field imaging, the DCs loaded with AuNVs showed
significantly more scattering due to the AuNPs com-
pared to untreated DCs with the same imaging exposure
(4 ms). The hyperspectral data showed that the loaded
DCs had a spectral shift toward 550 nm, close to the ab-
sorbance peak at 529 nm of AuNVs in solution, suggest-
ing that the enhanced scattering was caused by AuNPs
(Figure 3). The shift in the peak plasmon resonance
wavelength of AuNVs in cells compared to that in solu-
tion may be attributed to the higher refractive index
within cells and clustering of AuNVs within endosomes
or the cytosol.
Nanocarrier toxicity has been a significant limitation for
traditional formulations, such as liposomal or polymeric
nanocarriers. To evaluate whether the AuNVs induced
cytotoxicity in the DCs, we conducted alamarBlue viability
assays using a murine bone marrow-derived dendritic cell
line (JAWS II) after incubation with OVA or gp100
AuNVs at various concentrations for 24 h. The fluores-
cence intensities indicate cellular health and were normal-
ized to the cell control (media only). The viability did not
decrease following the addition of AuNVs (ranging from
127% to 155%) when compared to the media-only control
(100%) (Additional file 1: Figure S2). Interestingly, the
fluorescence intensities for all of the particle-treated JAWS
II conditions were significantly higher than the media-only
controls (p < 0.0015). alamarBlue measures cellular health
by cleavage of the metabolite into fluorescent molecules.
Improved metabolic activity may increase the amount ofTable 1 DLS results, polydispersity index, and zeta
potentials of citrate-capped gold colloids, COOH-PEG
-coated AuNPs, and OVA AuNVs
Size (nm) PDI Zeta (mV)
Colloids 33.5 ± 6.3 0.124 −37.6 ± 6.5
COOH-PEG-AuNPs 61.5 ± 6.2 0.201 −27.6 ± 12.2
OVA AuNVs 77.9 ± 9.5 0.305 −0.7 ± 6.7fluorescent by-product. Hence, the results suggest that
AuNVs may have caused dendritic cell activation by in-
creasing cellular activity, which can also enhance anti-
tumor immune responses.
Functional evaluation and optimization of AuNVs using
IFN-γ ELISPOTs
The functional characterization of the AuNVs was per-
formed in two parts: (1) simple splenocyte IFN-γ ELI-
SPOT assays for initial testing and (2) DC-to-splenocyte
ELISPOTs for design optimization. Design optimization
consisted of four sections: (1) conjugation method
optimization, (2) linker optimization, (3) AuNP core size
effects, and (4) peptide pool modifications. The ELI-
SPOT assays indirectly measures antigen-specific CD8+
CTL ability to secrete IFN-γ, which highly correlates to
anti-tumor immunogenicity [6,24]. Gp100 AuNVs were
used to stimulate gp100-specific T cells from pmel-1
transgenic mice, while OVA AuNVs were used to stimu-
late transgenic OT-I mice T cells [25].
At high particle concentrations (1011 particles/ml),
gp100 AuNVs were more potent in stimulating pmel-1
splenocytes (567 IFN-γ spot-forming cells (SFC)) com-
pared to mPEG-coated control AuNPs (322 SFC; p =
0.005), showing that the linked peptides conjugated on
the AuNVs remained functional (Figure 4). At particle
concentrations of 1010/ml, the AuNVs still had 191 SFC,
while the control AuNPs dropped to only 8 SFC. As the
particle concentration decreases, the AuNVs still showed
an effect up to 109 particles/ml, while at 108 particles/
ml, the effects were non-significant relative to the nega-
tive controls (media only) (Additional file 1: Figure S3).
The AuNV responses were consistently significantly
higher (p < 0.05) than the responses of the PEG-AuNPs,
thus showing that the AuNV effects were not solely
caused by the PEG or the AuNPs but due to the peptides
conjugated onto the particles (Figure 4). At higher par-
ticle concentrations, CTLs may be overloaded with par-
ticles, which in turn caused the elevated IFN-γ levels for
PEG-AuNP control groups.
For comparative analysis of the efficacy of AuNVs to
free peptides, the maximum dose was calculated by
multiplying the amount of peptide used to synthesize
each particle to the number of particles used. The max-
imum dose calculation allows a practical evaluation of
the cost and benefit of the AuNV design. It would not
be overall beneficial if the design required more raw
materials than the improvement of the efficacy com-
pared to free peptides. For 1010 particles/ml, the max-
imum dose is calculated to be 2.5 μg/ml. At this particle
concentration, the gp100 AuNVs (191 SFC) exhibit simi-
lar effects as the free-peptide control (172 SFC) (10 μg/
ml) with no significant difference. From this study, we
concluded that the AuNVs were able to induce strong
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fold efficiency of the free peptides.
Optimization of AuNV designs with DC-to-splenocyte IFN-
γ ELISPOTs
In vivo, antigens (or AuNVs) are uptaken by professional
APCs (i.e., DCs), and the TAA-derived peptides are sub-
sequently loaded onto major histocompatibility com-
plexes (MHCs) for stimulation of CD8+ CTLs and CD4+
helper T cells [26]. Previous ELISPOT assays exposed
AuNVs directly to splenocytes, which was a rudimentary
way to evaluate the effects of AuNVs. Although there0
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Figure 4 IFN-γ ELISPOT results from gp100 AuNV induction of pmel-1
threefold more IFN-γ secreting cells compared to the free-peptide control.
exhibited similar effects as the free-peptide control (10 μg/ml) with no signare some antigen-presenting cells in the splenocyte mix-
ture, the result would be occasionally inconclusive.
Thus, to mimic physiological conditions, the AuNVs
were incubated with dendritic cells prior to exposure to
the splenocytes, eliminating any AuNV direct influence
on the splenocytes. The BMDCs were cultured with
AuNVs for 24 h. Then, they were washed to remove ex-
cess AuNVs and were used as stimulator cells for
antigen-specific splenocytes on IFN-γ ELISPOT plates.
The DC-to-splenocyte ELISPOT assay can then be used
to determine whether the peptides conjugated onto
AuNPs can be free for MHC loading.1.E+10 Free Peptide
ntration (particles/mL)
gp100 AuNVs
n.s.
splenocytes. At 1011 particles/ml or 25 μg/ml, AuNVs stimulated
At 1010 particles/ml or 2.5 μg/ml maximum dose, the gp100 AuNVs
ificant difference (p = 0.4).
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improved peptide conjugation onto AuNVs: conjugation
duration and scheme. The optimization of conjugation
duration is critical for sufficient peptide polymerization
while minimizing unwanted cross-linking between the pep-
tide side chains. For conjugation efficiency, we compared
the efficacy of AuNVs with varying durations from 30 min
to 24 h. Figure 5A shows that AuNVs with 1-h conjugation
duration provided the highest IFN-γ secretion (52 SFC).
The AuNVs cross-linked for 2 h (24 SFC) were signifi-
cantly lower than the 1-h particles, while the 30-min
AuNVs (47 SFC) were not significantly different from the
1-h AuNVs.
To compare the hydrodynamic particle size of the par-
ticles, the DLS data showed that the 1-h conjugation
time formed the largest peptide-conjugated AuNVs (ap-
proximately 70 nm), which were still much smaller than
most liposomal and polymeric formulations (Additional
file 1: Figure S4) [8,9]. This advantage can potentially
improve lymphatic drainage of the AuNVs. The 2-h
AuNVs showed a smaller particle size that supports the
hypothesis that synthesis time can cause excessive cross-
linkage from the side groups on the peptides and fold on
top of the particle.
The scheme used for EDC/sulfo-NHS conjugation is
another important factor. As previously mentioned, the
conventional two-step conjugation method was designed
to minimize affecting the second protein's carboxyls.
However, in our situation, enhanced activation of pep-
tide carboxyl groups will be useful for allowing the pep-
tides to link together. Therefore, we designed a new
one-step conjugation scheme. The one-step method
used lower amounts of EDC/NHS, and the excess linkers
were not washed away. In this scenario, the process
remained in the MES buffer at pH 6. We hypothesized0
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Figure 5 gp100 AuNVs ELISPOT results for conjugation time optimiza
The DC-to-pmel-1 splenocyte ELISPOT results for the gp100 AuNVs at differ
stimulation results between the various incubation times (single asterisk de
comparison of the two-step and one-step method AuNV (double asterisk dthat the one-step method would be more effective at
forming chained peptides, and experimental results sup-
port that claim. Using the DC-to-splenocyte IFN-γ assay,
the one-step MES buffer method (231 SFC) was signifi-
cantly more effective in inducing IFN-γ secretion than
the two-step design (182 SFC; p = 0.004) (Figure 5B).
Therefore, the following experiments used the one-step
conjugation scheme.
Comparing efficacies of DNA linker and PEG linker AuNVs
Since PEG is non-degradable, using PEG as linkers raises
concern of whether the peptides were released from the
AuNPs, which is critical for MHC class I and II loading.
To address how peptides are released from the AuNVs
following conjugation with the PEG linkers, we exam-
ined the degradation of FITC-labeled AuNVs by cell pro-
teases from the JAWS II lysate, an immortalized BMDC
cell line. The FITC-labeled AuNVs were incubated with
the cell lysate for 24 h. Then, the mixture was centri-
fuged to remove all the particles and large cell debris.
The peptides that came off the particle would then be in
the supernatant. Both the OVA and gp100 AuNV
showed a twofold increase in the FITC fluorescent levels
in the supernatant post-lysate exposure, supporting the
hypothesis that cell proteases contained in DCs could
remove antigenic peptides from the surface of AuNPs
(Additional file 1: Figure S5).
By replacing the non-degradable PEG linkers with
poly-T DNA spacers, DNases in the cells would be
expected to degrade the spacer and release the peptides
from the particle surface. This release mechanism should
improve the immunogenicity of the AuNVs. The DNA
spacer (11 nt) had a thiol modification on the 50 end and
a primary amine on the 30 end. The thiol forms dative
bonds with AuNPs in a manner similar to that of PEG-NV
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instead of carboxyl groups. Thus, the carboxyl activation
step was removed because there were no longer any carb-
oxyl groups on the particles. This change, however, did de-
crease the peptide conjugation yield.
As previously mentioned, the BMDCs were incubated
with the AuNVs to minimize non-specific IFN-γ secre-
tion, Then, the loaded BMDCs were exposed to antigen-
specific splenocytes, i.e., OT-I for OVA peptides and
pmel-1 for gp100 peptides. When the AuNV-loaded
DCs were exposed to OT-I splenocytes, the AuNVs (134
SFC), maximum dose of 10 μg/ml, showed significant
improvement in IFN-γ secretion compared to the free-
peptide control (10 μg/ml; 103 SFC) (Figure 6A). Al-
though the improvement of the OVA AuNVs compared
to the OVA free peptides was not as large relative to the
gp100 AuNV samples, both tested AuNVs showed a sig-
nificant improvement in the splenocyte response com-
pared to the free peptides (p < 0.01) (Figure 6B).0
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The ELISPOT results in Figure 6B show that the DNA
spacers (8 SFC/μg) do not work as well as the PEG linker
(14 SFC/μg) for OVA on the AuNVs because their effects
were similar to those of free peptides (10 SFC/μg). How-
ever, the DNA spacer (17 SFC/μg) and PEG linker AuNVs
(19 SFC/μg) for gp100 showed significant improvement in
CTL stimulation.
To verify that the splenocyte IFN-γ induction is specific
to the correct peptides, we exposed the OVA and gp100
AuNVs to BMDCs and then exposed them to OT-I sple-
nocytes and pmel-1 splenocytes (Figure 6C). From the
ELISPOT results, the OT-I splenocytes responded signifi-
cantly more to the OVA AuNVs (135 SFC) than the gp100
AuNVs (96 SFC) and vice versa for pmel-1 (OVA, 36 SFC;
gp100, 289 SFC). Therefore, in addition to being simple,
versatile, and cost-effective, our AuNV design is highly
specific and non-toxic.0
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As noted above, the hydrodynamic particle size of the
AuNV can be important for particle migration to lymph
nodes. The AuNV size can be controlled by the size of the
core AuNP. We used DC-to-OT-I splenocyte ELISPOTs to
measure the size effects from 15-, 30-, and 80-nm OVA
AuNVs. This assay cannot test the subcutaneous draining
abilities of the AuNV particles and would require an in vivo
study to select the best core size. However, the results sug-
gest that particle size does not significantly alter the IFN-γ
efficacy using in vitro assays (Additional file 1: Figure S6).
All three particle size conditions had a maximum peptide
dose of 10 μg/ml, which correlates to 7 × 1011 particles/ml
for 15-nm cores, 1011 particles/ml for 30-nm cores, and
5.5 × 109 for 80-nm cores.
Peptide-pool AuNVs
To this point, the AuNV designs have been focused on
using MHC class I peptides. Although most vaccine
work has been focused on specific CD8+ T cells epitopes,
individual epitopes for all HLA types for MHC I and II
have not been identified. However, peptide pools are seg-
ments with overlapping amino acid (aa) sequences that
incorporate an entire antigen sequence.
The versatility of the AuNV design allows for conjuga-
tion of longer peptides or mixtures of peptides (i.e., pep-
tides pools) from different tumor antigens onto AuNPs.
The gp100 peptide pool, for example, has peptides that
are 15 aa in length with 11 aa overlaps. Including the en-
tire antigen sequence has three extra advantages: (1) the
natural cleavage sites are present to facilitate peptide re-
lease from the particles, (2) both the MHC class I and II
epitopes are included, and (3) peptide pools are easily
synthesized and can replace expensive and time-
consuming recombinant whole-protein isolation.
The gp100 peptide pool AuNVs were used in the
DC-to-pmel-1 splenocyte ELISPOTs, and the results show
that the average number of spots for the peptide
pool AuNVs was higher than that for the free-peptide pool
(Additional file 1: Figure S7). However, the peptide pool
AuNVs exhibited a much larger standard error and had a
non-significant difference between the AuNVs and the
free peptides (p = 0.34). This is because the assay only
evaluated one specific MHC class I epitope by using
pmel-1 splenocytes. Peptide-pool AuNVs may have several
other benefits that were not tested here, such as helper T
cell responses and facilitating peptide separation from the
particles due to preserved natural cleavage sites. These
effects may be very useful in in vivo settings.
Discussion
Gold nanoparticles are unique nanomaterials that are easy
to synthesize and modify. AuNPs have excellent optical
properties that can be exploited for detection orphotothermal applications. In addition, AuNPs accumulate
in phagocytic cells such as macrophages and dendritic cells,
making them ideal vehicles for vaccine delivery. Here, we
demonstrated a method to synthesize high-peptide density
gold nanovaccines using a simple self-assembling bottom-
up strategy. Changes in the absorbance spectra and TEM
images show successful peptide conjugation onto PEGy-
lated AuNPs. Calculating from the conjugation yield of
90%, each particle can carry up to 1,300 peptides. Moon
et al. [27] reported liposomal formulations to have an en-
capsulation efficiency of 200 to 350 μg OVA/mg of particles
and poly(lactic-co-glycolic acid) formulations to have 50 μg
OVA/mg of particles, while AuNVs correlate to roughly
500 μg of OVA peptide per milligram of AuNVs. Consider-
ing that gold also has a higher density than liposomal or
polymeric formulations, the amount of peptide carried by
AuNVs is much higher than that by other nanomaterials.
Not only does AuNVs have high peptide density, but we
also observed that AuNV behavior in solution depends on
the properties of the peptides that were used for conjuga-
tion. The OT-I peptides from the antigen OVA are neutral
in charge with an isoelectric point near physiological pH
(6.34). Thus, OVA AuNVs were easily suspended in PBS.
Ninety-four percent of the OVA AuNVs were recovered
throughout the multiple centrifugation and washing steps
with PBS. In comparison, the Trp-2 peptides are 78%
hydrophobic. The Trp-2 AuNVs adhered to the hydropho-
bic polypropylene tube after peptide conjugation was com-
pleted and did not detach during centrifugation or probe
sonication. However, the Trp-2 AuNVs remained in solu-
tion when ethanol (0.2% v/v Tween 20) was added to the
tubes due to the decrease in polarity of the solvent and the
addition of surfactants (Additional file 1: Figure S8). Thus,
AuNV particle behavior in solution is dependent on the
peptide properties.
Having high peptide density on AuNVs is important for
vaccine function because the peptide-coated nanocarriers
collect in the endosomes and can mimic the size of patho-
gens, stimulating DC maturation. The induction of DCs to
mature and to present tumor antigens is crucial for
engineering a successful vaccine. This stimulation by nano-
materials has been shown by Moon et al. to cause DCs
to induce large amounts of cross-presentation for
stronger and sustained anti-tumor immune responses
[27]. Cross-presentation is very important for CTL
stimulation because it is required to allow peptides to
enter the MHC class I (cytosolic) pathway from the
MHC class II (endosomal) pathway. By using MHC
class I peptides, DC-to-splenocyte ELISPOTs can be
used to evaluate the extent of cross-presentation. Add-
itionally, the assay itself is of interest because it can
screen large numbers of nanovaccines in vitro, simulat-
ing the process of antigen presentation and preventing
extensive use of animals.
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the peptides can come off the particles and enter the MHC
class I pathway. Therefore, the conjugation optimization of
conjugation duration and schemes is a key for an effective
AuNV. From the optimization results, we concluded that
the 1-h conjugation time was most effective. We
hypothesize that the peptides link linearly during the 1-h
conjugation but will begin to cross-link transversely via
peptide side groups by 2 h. The non-linear cross-linking
could disrupt the peptide sequence or presentability, thus
lowering the efficacy and size of those AuNVs.
As for the method optimization, the buffers used for the
conjugation process cause a significant impact on the
AuNV efficacy. MES buffer has a pKa of 6.15, which is
within the range for EDC coupling to carboxyl groups gen-
erating O-acylisourea [28,29]. Sulfo-NHS was then added
to replace the O-acylisourea to form semi-stable amine-
reactive NHS esters. Amine binding to the NHS esters
reacts better at neutral to higher pH [29]. Thus, switching
to PBS at pH 7.4 prevents excessive self cross-linkage.
Furthermore, the one-step (MES) method allows better
carboxyl activation and a higher chance of extra linkages or
cross-linkage, but it can also cause excessive cross-linkages
from the side changes of the peptides, which can lower the
efficacy of the vaccine peptides. Conversely, the two-step
method (MES-PBS) allows less side chain linkage but low-
ers overall peptide linkage. From the results, the one-step
method AuNVs were significantly better at stimulating
CTLs than the two-step method. Additionally, the one-
step method is more time- and cost-efficient because it
requires fewer reagents and less processing for improved
overall yield of particle collection.
After optimizing the conjugation time and method, we
investigated effects of different linkers such as DNA,
which should be degraded intracellularly and allow pep-
tide layers to be released from the gold surface. However,
the results show that PEG linker-based AuNVs were sig-
nificantly more effective at stimulating CTLs. The de-
crease in efficacy for the DNA-linked OVA AuNVs is
probably due to two factors. First, the lack of activated
carboxyl groups (i.e., PEG linker AuNVs) results in the de-
ficiency to form polymerization points. Therefore, insuffi-
cient peptide polymerization is caused by excessive
peptide self-polymerization off the AuNPs to form small
peptide clumps in the solution. Second, there is a reduced
amount of linkers on the AuNPs because the DNA spacer
requires more foot space than the PEG linker [30,31].
Overall, the data here suggest that the PEG linker design
provides the best AuNVs for both peptide types.
Conclusions
In conclusion, improving vaccine delivery using nanocar-
riers can stimulate a sustained anti-tumor response
while inducing activation and maturation of DCs. Here,we designed AuNVs by self-assembling modified PEGs
and tumor-associated antigen peptides on gold nanopar-
ticle surfaces. AuNVs carry large doses of peptides by
using a simple bottom-up conjugation strategy to layer
peptides onto the PEG-modified AuNPs. We showed
that the simple AuNV design improved in vitro immune
cell stimulation while maintaining a sub-100-nm diam-
eter size to allow effective delivery and improve im-
munogenicity of vaccine antigen peptides such as
ovalbumin and gp100.
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